Crispr Therapeutics (NASDAQ:CRSP) had its target price lifted by investment analysts at Goldman Sachs Group from $52.00 to $75.00 in a report released on Tuesday, November 19th, The Fly reports. The firm currently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 14.75% from the stock’s previous close.
Other equities research analysts have also issued research reports about the stock. Piper Jaffray Companies reissued an “overweight” rating on shares of Crispr Therapeutics in a report on Monday, October 21st. Roth Capital raised their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a report on Tuesday, July 30th. William Blair reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 30th. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Finally, Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus target price of $69.54.
Shares of CRSP stock traded down $0.67 on Tuesday, hitting $65.36. 737,055 shares of the company’s stock traded hands, compared to its average volume of 1,674,626. The stock has a market capitalization of $3.65 billion, a price-to-earnings ratio of -19.00 and a beta of 3.31. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company’s fifty day simple moving average is $58.93 and its 200 day simple moving average is $48.44.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Benjamin Edwards Inc. lifted its position in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc raised its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares during the last quarter. US Bancorp DE raised its holdings in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new position in Crispr Therapeutics in the third quarter worth about $26,000. Finally, BSW Wealth Partners purchased a new position in Crispr Therapeutics in the second quarter worth about $39,000. 49.82% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Why do commodities matter?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.